



Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

May 8, 2025

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS[®]), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter.

Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the [Investors](#) section of the Company's website.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS[®]) to improve patient outcomes. Clearside's SCS injection platform, utilizing the Company's patented SCS Microinjector[®], enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, [CLS-AX \(axitinib injectable suspension\)](#), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, [XIPERE[®] \(triamcinolone acetonide injectable suspension\)](#) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on [LinkedIn](#) and [X](#).

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com

Source: Clearside Biomedical, Inc.